SCHEMBL3976362

SCHEMBL3976362

CCOC(=O)c1c[nH]c2ccc(I)c(C)c2c1=O

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.56
GABRB2 P47870 3/20 0.56
GABRB1 P18505 2/20 0.55
GABRA3 P34903 2/20 0.55
CLEC4M Q9H2X3 1/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 2/20 0.44
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2970181 0.78 CLEC4M (0.58) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL396948 0.77 CLEC4M (0.56) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL5305475 0.77 GABRA1 (0.59) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL10478138 0.77 GABRA1 (0.54) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL23731297 0.77 GABRA1 (0.51) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL2285923 0.76 CLEC4M (0.55) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL30898569 0.76 GABRA1 (0.74) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL1211778 0.76 GABRA1 (0.74) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL28752415 0.76 NR4A2 (0.59) GABRA1GABRB2GABRB1GABRA3CLEC4M
SCHEMBL11512243 0.76 GABRA1 (0.53) GABRA1GABRB2GABRB1GABRA3CLEC4M

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569550-B2 14 and 15 membered ring compounds GLAXO GROUP LIMITED (GB) 2009-08-04 US disclosed
US-20070185117-A1 Novel 14 and 15 membrered ring compounds GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
EP-1628988-B1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LTD (GB) 2006-10-04 EP disclosed
EP-1628988-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-03-01 EP disclosed
WO-2004101586-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185117-A1 Novel 14 and 15 membrered ring compounds CYP51A1, LSS, IL17A GABRA1 2234/4885GABRB2 2195/4885GABRB1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.